Lebanon Pharmaceuticals & Healthcare Report Q1 2015
Headline Expenditure Projections
- Pharmaceuticals : LBP2,206.25bn (USD1.46bn) in 2013 to LBP2,407.82bn (USD1.53bn) in 2014; +9.1% in local currency and +4.4.% in US dollar terms. Forecast revised upwards to better suit current market conditions.
- Healthcare: LBP5,150.35bn (USD3.42bn) in 2013 to LBP5,578.71bn (USD3.54bn) in 2014; +8.3% in local currency and +3.7% US dollar terms. Forecast adjusted to better suit current market conditions.
For Q1 2015, Lebanon's Pharmaceutical Risk/Reward Index (RRI) score is calculated at 54.7 out of 100, higher than last quarter's score of 53.9, and ranking the country seventh in the Middle East and Africa matrix, one place below last quarter's sixth position.
Key Trends & Developments
Lebanese Health Hinister Wael Abu Faour has announced that the health ministry has developed a strategy aiming to establish that quality pharmaceutical products are sold in the local market amid the proliferation of fake medicines in Lebanon. Faour cautioned that the local pharmaceutical 'markets are rife with counterfeit pharmaceuticals', reported the Daily Star. Faour also stated that the health ministry has taken a 'qualitative step' in lowering medicine prices by 22% across the country. Pharmaceutical firms have not seen any negative impact from the price reductions, as profit lost due to the reduction only lowered the 'surplus profits', according to Faour.
US-based Mercy Health System has introduced initiatives in virtual healthcare that will allow patients...
The Lebanon Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Lebanon Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Lebanese pharmaceutical and healthcare industry.
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Lebanon to test other views - a key input for successful budgeting and strategic business planning in the Lebanese pharmaceutical and healthcare market.
- Target business opportunities and risks in the Lebanese pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Lebanon.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
The influx of Syrian refugees into Lebanon is putting a strain on the healthcare system, which is unable to meet the additional demand for treatment. Elevated political instability is putting the pharmaceutical sector at risk in terms of government policy relating to healthcare, while a poor economic outlook is detrimental to the ability to pay for medicine. We expect the continuation of the Syrian civil war to hamper growth in this market.
BMI Industry View
Pharmaeutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lebanon 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2010-2018)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lebanon 2010-2018)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lebanon 2010-2018)
Generic Drug Market Forecast
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Lebanon 2010-2018)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lebanon 2010-2018)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Lebanon 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Lebanon 2012-2018)
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Table: Lebanon - Economic Activity
Industry Risk Reward Ratings
Middle East & Africa Risk/Reward Ratings
Lebanon Risk/Reward Ratings
Industry Trends And Developments
Regional Healthcare Collaboration
Public Sector Procurement
Intellectual Property Regime
Free Trade Agreements
Pharmaceutical Sector Developments
Retail Pharmacy Sector
Benta Pharnaceutical Industries (BPI)
Chalhoub Pharmaceuticals (CHAPHA)
Merck & Co
Johnson & Johnson (J&J)
Table: Lebanon's Population By Age Group, 1990-2020 ('000)
Table: Lebanon's Population By Age Group, 1990-2020 (% of total)
Table: Lebanon's Key Population Ratios, 1990-2020
Table: Lebanon's Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Ratings Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it